Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors

@article{Yoshimi2014EffectsOB,
  title={Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors},
  author={N. Yoshimi and Y. Fujita and Y. Ohgi and T. Futamura and K. Hashimoto},
  journal={Pharmacology Biochemistry and Behavior},
  year={2014},
  volume={124},
  pages={245-249}
}
  • N. Yoshimi, Y. Fujita, +2 authors K. Hashimoto
  • Published 2014
  • Psychology, Medicine
  • Pharmacology Biochemistry and Behavior
  • Brexpiprazole, a serotonin-dopamine activity modulator, is currently being tested in clinical trials as a new therapy for a number of neuropsychiatric diseases, including schizophrenia and major depressive disorder. Accumulating evidence suggests that 5-hydroxytryptamine (5-HT)1A receptors play a role in cognition. This study was undertaken to examine whether brexpiprazole, a novel drug with 5-HT1A receptor partial agonism, could improve cognitive deficits in mice, induced by repeated… CONTINUE READING
    31 Citations
    Acute Effects of Brexpiprazole on Serotonin, Dopamine, and Norepinephrine Systems: An In Vivo Electrophysiologic Characterization
    • 32
    • PDF
    Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator
    • 32
    The antipsychotic drug brexpiprazole reverses phencyclidine-induced disruptions of thalamocortical networks
    • 2
    • PDF
    Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown—a model of mania
    • 9
    • Highly Influenced
    Brexpiprazole Alters Monoaminergic Systems following Repeated Administration: an in Vivo Electrophysiological Study
    • 11
    • PDF

    References

    SHOWING 1-10 OF 51 REFERENCES
    Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator
    • 158
    • PDF